Metraipolis › archive › dc_8bd2dab4f015

Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential — Europe PMC PMID:42797274

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42797274
DOI
10.3390/pharmaceutics18091099
License (as archived)
solo-consultazione
Archived
2026-10-16T11:28:45.094Z
SHA-256 of the archived text
430f243854c51a3d7a563baa59d3f24a9ccf4e7e5c3c5dcb0c825db4b9d3ff16
Stable URL of this page
https://metraipolis.com/documento/dc_8bd2dab4f015

How to cite

Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential — Europe PMC PMID:42797274 — Europe PMC (en), https://europepmc.org/article/MED/42797274 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8bd2dab4f015 (Metraipolis archive dc_8bd2dab4f015, sha256 430f243854c51a3d7a563baa59d3f24a9ccf4e7e5c3c5dcb0c825db4b9d3ff16)
BibTeX
@misc{dc8bd2dab4f015,
  title = {Nose-to-Brain Therapeutics in Parkinson's Disease: Clinical Trials, Mechanisms, and Therapeutic Potential — Europe PMC PMID:42797274},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42797274},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8bd2dab4f015; sha256 430f243854c51a3d7a563baa59d3f24a9ccf4e7e5c3c5dcb0c825db4b9d3ff16},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42797274. Agents can read the archived copy with the MCP tool read_document.